Scott Bizily sold $92k of FDMT
Chief Legal Officer at 4D Molecular Therapeutics, Inc.. 6,566 shares at an average of $14.00, traded Jun 30, 2026, filed Jul 2, 2026.
Score components
- +15RoleOfficer
- +9Trade size$92k at market
- +10Share of holdings soldSold 43% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001920738-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | MOption exercise Common Stock10b5-1 | +814 | $4.14 | $3,370 | 9,431 | Jul 2, 2026 |
| Jun 30, 2026 | MOption exercise Common Stock10b5-1 | +5,752 | $6.49 | $37k | 15,183 | Jul 2, 2026 |
| Jun 30, 2026 | SOpen-market sale Common Stock10b5-1 | -6,566 | $14.00 | $92k | 8,617 | Jul 2, 2026 |
| Jun 30, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -814 | $0.00 | $0 | 62,971 | Jul 2, 2026 |
| Jun 30, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,752 | $0.00 | $0 | 3,543 | Jul 2, 2026 |
Related signals
Other insiders at 4D Molecular Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 17Weak | 4D Molecular Therapeutics, Inc. | David Kirn See Remarks | $754k 58,333 shares | -8% | |
| 0Weak | 4D Molecular Therapeutics, Inc. | Scott Bizily Chief Legal Officer | $22k 1,635 shares | -16% | |
| 25Weak | 4D Molecular Therapeutics, Inc. | David Kirn See Remarks | $811k 58,333 shares | -7% | |
| 0Weak | 4D Molecular Therapeutics, Inc. | Scott Bizily Chief Legal Officer | $8,176 584 shares | -6% | |
| 13Weak | 4D Molecular Therapeutics, Inc. | David Kirn See Remarks | $1.1M 69,076 shares | -8% | |
| 4Weak | 4D Molecular Therapeutics, Inc. | Scott Bizily Chief Legal Officer | $40k 3,270 shares | -32% | |
| 16Weak | 4D Molecular Therapeutics, Inc. | David Kirn See Remarks | $275k 26,842 shares | -3% | |
| 13Weak | 4D Molecular Therapeutics, Inc. | David Kirn See Remarks | $125k 12,415 shares | -1% | |
| 24Weak | 4D Molecular Therapeutics, Inc. | David Kirn See Remarks | $737k 58,333 shares | -6% | |
| 18Weak | 4D Molecular Therapeutics, Inc. | Scott Bizily Chief Legal Officer | $118k 9,810 shares | -53% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.